- Advanced search
Receptor tyrosine kinases (RTKs), a family of cell-surface receptors, which transduce signals to polypeptide and protein hormones, cytokines and growth factors are key regulators of critical cellular processes, such as proliferation and differentiation, cell survival and metabolism, cell migration and cell cycle control [1-2,4]. In the human genome, 58 RTKs have been identified, which fall into 20 families .
All RTKs display an extracellular ligand binding domain, a single transmembrane helix, a cytoplasmic region containing the protein tyrosine kinase activity (occasionally split into two domains by an insertion, termed the kinase insertion), with juxta-membrane and C-terminal regulatory regions. Agonist binding to the extracellular domain evokes dimerization, and sometimes oligomerization, of RTKs (a small subset of RTKs forms multimers even in the absence of activating ligand). This leads to autophosphorylation in the tyrosine kinase domain in a trans orientation, serving as a site of assembly of protein complexes and stimulation of multiple signal transduction pathways, including phospholipase C-γ, mitogen-activated protein kinases and phosphatidylinositol 3-kinase .
RTKs are of widespread interest not only through physiological functions, but also as drug targets in many types of cancer and other disease states. Many diseases result from genetic changes or abnormalities that either alter the activity, abundance, cellular distribution and/or regulation of RTKs. Therefore, drugs that modify the dysregulated functions of these RTKs have been developed which fall into two categories. One group is often described as ‘biologicals’, which block the activation of RTKs directly or by chelating the cognate ligands, while the second are small molecules designed to inhibit the tyrosine kinase activity directly.
* Key recommended reading is highlighted with an asterisk
* Alsina FC, Ledda F, Paratcha G. (2012) New insights into the control of neurotrophic growth factor receptor signaling: implications for nervous system development and repair. J. Neurochem., 123 (5): 652-61. [PMID:22994539]
* Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. (2012) Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol, 9 (1): 16-32. [PMID:22124364]
* Camidge DR, Doebele RC. (2012) Treating ALK-positive lung cancer--early successes and future challenges. Nat Rev Clin Oncol, 9 (5): 268-77. [PMID:22473102]
* Chen Y, Fu AK, Ip NY. (2012) Eph receptors at synapses: implications in neurodegenerative diseases. Cell. Signal., 24 (3): 606-11. [PMID:22120527]
* Fu HL, Valiathan RR, Arkwright R, Sohail A, Mihai C, Kumarasiri M, Mahasenan KV, Mobashery S, Huang P, Agarwal G et al.. (2013) Discoidin domain receptors: unique receptor tyrosine kinases in collagen-mediated signaling. J. Biol. Chem., 288 (11): 7430-7. [PMID:23335507]
* Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. (2012) Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer, 12 (2): 89-103. [PMID:22270953]
* Goetz R, Mohammadi M. (2013) Exploring mechanisms of FGF signalling through the lens of structural biology. Nat. Rev. Mol. Cell Biol., 14 (3): 166-80. [PMID:23403721]
* Guillemot F, Zimmer C. (2011) From cradle to grave: the multiple roles of fibroblast growth factors in neural development. Neuron, 71 (4): 574-88. [PMID:21867876]
* Higashiyama S, Nanba D, Nakayama H, Inoue H, Fukuda S. (2011) Ectodomain shedding and remnant peptide signalling of EGFRs and their ligands. J. Biochem., 150 (1): 15-22. [PMID:21610047]
* Ibáñez CF, Simi A. (2012) p75 neurotrophin receptor signaling in nervous system injury and degeneration: paradox and opportunity. Trends Neurosci., 35 (7): 431-40. [PMID:22503537]
* Koh GY. (2013) Orchestral actions of angiopoietin-1 in vascular regeneration. Trends Mol Med, 19 (1): 31-9. [PMID:23182855]
* Larsen AK, Ouaret D, El Ouadrani K, Petitprez A. (2011) Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol. Ther., 131 (1): 80-90. [PMID:21439312]
* Lefebvre J, Ancot F, Leroy C, Muharram G, Lemière A, Tulasne D. (2012) Met degradation: more than one stone to shoot a receptor down. FASEB J., 26 (4): 1387-99. [PMID:22223753]
* Leitinger B. (2011) Transmembrane collagen receptors. Annu. Rev. Cell Dev. Biol., 27: 265-90. [PMID:21568710]
* Lennartsson J, Rönnstrand L. (2012) Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol. Rev., 92 (4): 1619-49. [PMID:23073628]
* Liang G, Liu Z, Wu J, Cai Y, Li X. (2012) Anticancer molecules targeting fibroblast growth factor receptors. Trends Pharmacol. Sci., 33 (10): 531-41. [PMID:22884522]
* Lisle JE, Mertens-Walker I, Rutkowski R, Herington AC, Stephenson SA. (2013) Eph receptors and their ligands: promising molecular biomarkers and therapeutic targets in prostate cancer. Biochim. Biophys. Acta, 1835 (2): 243-57. [PMID:23396052]
* Lu B, Nagappan G, Guan X, Nathan PJ, Wren P. (2013) BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat. Rev. Neurosci., 14 (6): 401-16. [PMID:23674053]
* Morandi A, Plaza-Menacho I, Isacke CM. (2011) RET in breast cancer: functional and therapeutic implications. Trends Mol Med, 17 (3): 149-57. [PMID:21251878]
* Peters S, Adjei AA. (2012) MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol, 9 (6): 314-26. [PMID:22566105]
* Roskoski Jr R. (2013) Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. Pharmacol. Res., 68 (1): 68-94. [PMID:23201355]
* Sheffler-Collins SI, Dalva MB. (2012) EphBs: an integral link between synaptic function and synaptopathies. Trends Neurosci., 35 (5): 293-304. [PMID:22516618]
* Shibuya M. (2013) Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J. Biochem., 153 (1): 13-9. [PMID:23172303]
* Turner CA, Watson SJ, Akil H. (2012) The fibroblast growth factor family: neuromodulation of affective behavior. Neuron, 76 (1): 160-74. [PMID:23040813]
* Woo KV, Baldwin HS. (2011) Role of Tie1 in shear stress and atherosclerosis. Trends Cardiovasc. Med., 21 (4): 118-23. [PMID:22681967]
* Yamanashi Y, Tezuka T, Yokoyama K. (2012) Activation of receptor protein-tyrosine kinases from the cytoplasmic compartment. J. Biochem., 151 (4): 353-9. [PMID:22343747]
1. Blume-Jensen P, Hunter T. (2001) Oncogenic kinase signalling. Nature, 411 (6835): 355-65. [PMID:11357143]
2. Grassot J, Mouchiroud G, Perrière G. (2003) RTKdb: database of Receptor Tyrosine Kinase. Nucleic Acids Res., 31 (1): 353-8. [PMID:12520021]
3. Lemmon MA, Schlessinger J. (2010) Cell signaling by receptor tyrosine kinases. Cell, 141 (7): 1117-34. [PMID:20602996]
4. Ullrich A, Schlessinger J. (1990) Signal transduction by receptors with tyrosine kinase activity. Cell, 61 (2): 203-12. [PMID:2158859]
Database page citation:
Receptor tyrosine kinases (RTKs). Accessed on 29/03/2017. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=304.
Concise Guide to PHARMACOLOGY citation:
Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Southan C, Davies JA and CGTP Collaborators (2015) The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol. 172: 6024-6109.